CA2929715A1 - Methodes d'inhibition de la kinase tie2 utiles dans le traitement du cancer - Google Patents

Methodes d'inhibition de la kinase tie2 utiles dans le traitement du cancer Download PDF

Info

Publication number
CA2929715A1
CA2929715A1 CA2929715A CA2929715A CA2929715A1 CA 2929715 A1 CA2929715 A1 CA 2929715A1 CA 2929715 A CA2929715 A CA 2929715A CA 2929715 A CA2929715 A CA 2929715A CA 2929715 A1 CA2929715 A1 CA 2929715A1
Authority
CA
Canada
Prior art keywords
formula
composition
combination
methods
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2929715A
Other languages
English (en)
Inventor
Daniel L. Flynn
Michael D. Kaufman
Bryan Smith
Marc S. RUDOLTZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Deciphera Pharmaceuticals LLC
Original Assignee
Deciphera Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deciphera Pharmaceuticals LLC filed Critical Deciphera Pharmaceuticals LLC
Publication of CA2929715A1 publication Critical patent/CA2929715A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des méthodes d'inhibition de la kinase TIE2 utiles dans le traitement de la croissance tumorale, de l'envahissement tumoral, de l'intravasion, de la dissémination tumorale, des métastases et de l'immunosuppression. L'invention concerne en particulier des méthodes d'utilisation de 1-(3-tert-butyl-1-(quinolin-6-yl)-1Hpyrazol- 5-yl)-3-(2-fluoro-4-(2-(méthylcarbamoyl)pyridin-4-yloxy)phényl)urée et de ses sels de Formule I.
CA2929715A 2013-11-07 2013-11-07 Methodes d'inhibition de la kinase tie2 utiles dans le traitement du cancer Abandoned CA2929715A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2013/069005 WO2015069266A1 (fr) 2013-11-07 2013-11-07 Méthodes d'inhibition de la kinase tie2 utiles dans le traitement du cancer

Publications (1)

Publication Number Publication Date
CA2929715A1 true CA2929715A1 (fr) 2015-05-14

Family

ID=53041876

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2929715A Abandoned CA2929715A1 (fr) 2013-11-07 2013-11-07 Methodes d'inhibition de la kinase tie2 utiles dans le traitement du cancer

Country Status (7)

Country Link
EP (1) EP3065549A4 (fr)
JP (1) JP6568093B2 (fr)
KR (2) KR20210063475A (fr)
CN (2) CN105873440B (fr)
AU (3) AU2013404949B2 (fr)
CA (1) CA2929715A1 (fr)
WO (1) WO2015069266A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
WO2015069266A1 (fr) * 2013-11-07 2015-05-14 Flynn Daniel L Méthodes d'inhibition de la kinase tie2 utiles dans le traitement du cancer
EP3102605B1 (fr) 2014-02-04 2018-11-14 Pfizer Inc Association d'un antagoniste du pd-1 et d'un inhibiteur du vegfr pour traiter le cancer
SG11201706918YA (en) 2015-02-26 2017-09-28 Merck Patent Gmbh Pd-1 / pd-l1 inhibitors for the treatment of cancer
US20180106811A1 (en) * 2015-05-27 2018-04-19 Albert Einstein College Of Medicine, Inc. Tmem active test and uses thereof in diagnosis, prognosis and treatment of tumors
MX2017016324A (es) 2015-06-16 2018-03-02 Merck Patent Gmbh Tratamientos de combinacion de antagonista de ligando 1 de muerte programada (pd-l1).
AU2017225982B2 (en) 2016-03-02 2023-10-05 Eisai R&D Management Co., Ltd. Eribulin-based antibody-drug conjugates and methods of use
WO2017172734A1 (fr) 2016-03-29 2017-10-05 Mayo Foundation For Medical Education And Research Traitement de métastases cancéreuses
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
AU2017339856A1 (en) 2016-10-06 2019-05-23 Merck Patent Gmbh Dosing regimen of avelumab for the treatment of cancer
CA3049926A1 (fr) 2017-01-17 2018-07-26 Heparegenix Gmbh Inhibiteurs de proteine kinase pour favoriser la regeneration du foie, ou pour reduire ou prevenir la mort des hepatocytes
CN106822128A (zh) * 2017-02-24 2017-06-13 南华大学附属第医院 酪氨酸激酶抑制剂dcc‑2036的新应用
KR20200115607A (ko) 2018-01-31 2020-10-07 데시페라 파마슈티칼스, 엘엘씨. 위장관 기질 종양의 치료를 위한 병용 요법
CN110003181B (zh) * 2019-05-22 2020-08-28 北京凯恩梅格医药科技有限公司 一种基于克唑替尼结构的c-Met/HDAC双靶点抑制剂及其合成方法与应用
AU2020329956B2 (en) 2019-08-12 2023-11-16 Deciphera Pharmaceuticals, Llc. Ripretinib for treating gastrointestinal stromal tumors
EP4013417A1 (fr) * 2019-08-12 2022-06-22 Deciphera Pharmaceuticals, LLC Procédés et compositions pour traiter des malformations vasculaires
TW202122082A (zh) 2019-08-12 2021-06-16 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
CN112812109B (zh) * 2019-11-18 2022-06-21 中国科学院微生物研究所 化合物DaP-01及其制备方法和应用
MX2022008097A (es) 2019-12-30 2022-09-19 Deciphera Pharmaceuticals Llc Composiciones de 1-(4-bromo-5-(1-etil-7-(metilamino)-2-oxo-1,2-dih idro-1,6-naftiridin-3-yl)-2-fluorofeil)-3-fenilurea.
CN115135308A (zh) 2019-12-30 2022-09-30 德西费拉制药有限责任公司 非晶型激酶抑制剂制剂及其使用方法
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130023587A1 (en) * 2010-04-01 2013-01-24 Duke University Compositions and methods for the treatment of cancer
US9296722B2 (en) * 2010-05-27 2016-03-29 Ambit Biosciences Corporation Azolyl urea compounds and methods of use thereof
AU2012205601B2 (en) * 2011-01-11 2016-03-24 Novartis Ag Combination
JP6158180B2 (ja) * 2011-07-29 2017-07-05 メディベイション プロステイト セラピューティクス， インコーポレイテッド 乳がんの処置
WO2013036232A2 (fr) * 2011-09-08 2013-03-14 Deciphera Pharmaceuticals, Llc Méthodes et compositions pouvant être utilisées en vue du traitement de maladies myéloprolifératives et d'autres maladies prolifératives
WO2013043569A1 (fr) * 2011-09-20 2013-03-28 Vical Incorporated Immunothérapie combinée à action antitumorale synergique faisant appel à des alloantigènes
WO2015069266A1 (fr) * 2013-11-07 2015-05-14 Flynn Daniel L Méthodes d'inhibition de la kinase tie2 utiles dans le traitement du cancer

Also Published As

Publication number Publication date
JP6568093B2 (ja) 2019-08-28
KR20210063475A (ko) 2021-06-01
JP2017500371A (ja) 2017-01-05
CN108464981B (zh) 2022-06-24
CN105873440B (zh) 2018-06-01
AU2013404949A1 (en) 2016-05-26
AU2021200113A1 (en) 2021-03-04
AU2013404949B2 (en) 2018-10-18
AU2019200261A1 (en) 2019-01-31
EP3065549A1 (fr) 2016-09-14
WO2015069266A1 (fr) 2015-05-14
CN105873440A (zh) 2016-08-17
KR20160070188A (ko) 2016-06-17
EP3065549A4 (fr) 2017-05-24
CN108464981A (zh) 2018-08-31

Similar Documents

Publication Publication Date Title
US9457019B2 (en) Methods for inhibiting tie-2 kinase useful in the treatment of cancer
AU2021200113A1 (en) Methods for inhibiting tie2 kinase useful in the treatment of cancer
JP5656823B2 (ja) 抗ｈｅｒ２抗体−薬剤コンジュゲートと化学療法剤の併用及び使用方法
ES2622527T3 (es) Inhibidores de CSF-1R para el tratamiento de tumores de cerebro
US8435992B2 (en) Multiple myeloma treatments
US9682082B2 (en) Combinations of AKT and MEK inhibitor compounds, and methods of use
JP2017503842A (ja) 癌治療のためのアピリモド（ａｐｉｌｉｍｏｄ）組成物
KR20210034613A (ko) 퀴놀린 유도체 및 항체의 약물 조합
JP2023036999A (ja) 免疫応答を調節するためのオキサビシクロヘプタン
US11357766B2 (en) Compositions and methods for treating cancer
CN110891944B (zh) 用于治疗癌症的化合物、组合物及其用途
US20220047573A1 (en) Methods for treating vascular malformations
JP6945587B2 (ja) ガンの処置に有用なｔｉｅ２キナーゼの阻害方法
JP7420402B2 (ja) 免疫チェックポイント分子の発現抑制剤
KR20150092760A (ko) Pi3k/akt 저해제 화합물과 her3/egfr 저해제 화합물의 조합 및 과다증식성 장애의 치료에 있어서의 이의 용도
JP2015503568A (ja) トラスツズマブに不応性の乳癌の治療方法
EP4013417A1 (fr) Procédés et compositions pour traiter des malformations vasculaires
KR20240001703A (ko) 유비퀴틴 특이적 펩티다제 22 (usp22)의 억제제 및 질환 및 장애를 치료하기 위한 그의 용도
CN116568326A (zh) 用于治疗实体瘤的方法及包括krasg12c抑制剂和vegf抑制剂的组合物
CA3065574A1 (fr) Identification et utilisation d'agents ameliorant la destruction de cellules cibles specifiques a un antigene de lymphocyte t cytotoxique (ctl)
AU2015203865A1 (en) Use of 2-carboxamide cycloamino urea derivatives in the treatment of EGFR dependent diseases or diseases that have acquired resistance to agents that target EGFR family members
NZ617243B2 (en) Combinations of akt and mek inhibitor compounds, and methods of use

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20181107

EEER Examination request

Effective date: 20181107

EEER Examination request

Effective date: 20181107

EEER Examination request

Effective date: 20181107

EEER Examination request

Effective date: 20181107

FZDE Discontinued

Effective date: 20240221